Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Ann Oncol ; 27(2): 306-14, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26598546

RESUMO

BACKGROUND: ALK-negative anaplastic large cell lymphoma associated with breast implant (i-ALCL) has been recently recognized as a distinct entity. Among 43 830 lymphomas registered in the French Lymphopath network since 2010, 300 breast lymphomas comprising 25 peripheral T-cell lymphomas (PTCL) were reviewed. Among PTCL, ALK-negative ALCL was the most frequent and all of them were associated with breast implants. PATIENTS AND METHODS: Since 2010, all i-ALCL cases were collected from different institutions through Lymphopath. Immuno-morphologic features, molecular data and clinical outcome of 19 i-ALCLs have been retrospectively analyzed. RESULTS: The median age of the patients was 61 years and the median length between breast implant and i-ALCL was 9 years. Most implants were silicone-filled and textured. Implant removal was performed in 17 out of 19 patients with additional treatment based on mostly CHOP or CHOP-like chemotherapy regimens (n = 10/19) or irradiation (n = 1/19). CHOP alone or ABVD following radiation without implant removal have been given in two patients. The two clinical presentations, i.e. effusion and less frequently tumor mass correlated with distinct histopathologic features: in situ i-ALCL (anaplastic cell proliferation confined to the fibrous capsule) and infiltrative i-ALCL (pleomorphic cells massively infiltrating adjacent tissue with eosinophils and sometimes Reed-Sternberg-like cells mimicking Hodgkin lymphoma). Malignant cells were CD30-positive, showed a variable staining for EMA and were ALK negative. Most cases had a cytotoxic T-cell immunophenotype with variable T-cell antigen loss and pSTAT3 nuclear expression. T-cell receptor genes were clonally rearranged in 13 out of 13 tested cases. After 18 months of median follow-up, the 2-year overall survival for in situ and infiltrative i-ALCL was 100% and 52.5%, respectively. CONCLUSIONS: In situ i-ALCLs have an indolent clinical course and generally remain free of disease after implant removal. However, infiltrative i-ALCLs could have a more aggressive clinical course that might require additional therapy to implant removal.


Assuntos
Implantes de Mama/efeitos adversos , Linfoma Anaplásico de Células Grandes/patologia , Linfoma de Células T Periférico/patologia , Silicones/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Quinase do Linfoma Anaplásico , Feminino , Doença de Hodgkin/patologia , Humanos , Imunofenotipagem , Antígeno Ki-1/metabolismo , Linfoma Anaplásico de Células Grandes/induzido quimicamente , Linfoma Anaplásico de Células Grandes/mortalidade , Linfoma de Células T Periférico/induzido quimicamente , Linfoma de Células T Periférico/mortalidade , Pessoa de Meia-Idade , Receptores Proteína Tirosina Quinases/metabolismo , Receptores de Antígenos de Linfócitos T/metabolismo , Estudos Retrospectivos , Fator de Transcrição STAT3/metabolismo , Linfócitos T Citotóxicos/imunologia
2.
ESMO Open ; 6(1): 100044, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33516148

RESUMO

BACKGROUND: Second primary cancers (SPCs) are diagnosed in over 5% of patients after a first primary cancer (FPC). We explore here the impact of immune checkpoint inhibitors (ICIs) given for an FPC on the risk of SPC in different age groups, cancer types and treatments. PATIENTS AND METHODS: The files of the 46 829 patients diagnosed with an FPC in the Centre Léon Bérard from 2013 to 2018 were analyzed. Structured data were extracted and electronic patient records were screened using a natural language processing tool, with validation using manual screening of 2818 files of patients. Univariate and multivariate analyses of the incidence of SPC according to patient characteristics and treatment were conducted. RESULTS: Among the 46 829 patients, 1830 (3.9%) had a diagnosis of SPC with a median interval of 11.1 months (range 0-78 months); 18 128 (38.7%) received cytotoxic chemotherapy (CC) and 1163 (2.5%) received ICIs for the treatment of the FPC in this period. SPCs were observed in 7/1163 (0.6%) patients who had received ICIs for their FPC versus 437/16 997 (2.6%) patients receiving CC and no ICIs for the FPC versus 1386/28 669 (4.8%) for patients receiving neither CC nor ICIs for the FPC. This reduction was observed at all ages and for all histotypes analyzed. Treatment with ICIs and/or CC for the FPC are associated with a reduced risk of SPC in multivariate analysis. CONCLUSION: Immunotherapy with ICIs alone and in combination with CC was found to be associated with a reduced incidence of SPC for all ages and cancer types.


Assuntos
Inibidores de Checkpoint Imunológico , Segunda Neoplasia Primária , Humanos , Incidência , Segunda Neoplasia Primária/epidemiologia
3.
Rev Med Interne ; 29(7): 573-6, 2008 Jul.
Artigo em Francês | MEDLINE | ID: mdl-18243425

RESUMO

INTRODUCTION: Agnogenic myeloid metaplasia, associated with myelofibrosis, is a myeloproliferative disorder. Extramedullary hematopoiesis in the pleura is rare and its prognosis is often severe. EXEGESIS: Herein we report a 64-year-old woman, who presented with pleural extramedullary hematopoiesis, treated by hydroxyurea-based chemotherapy with disease control. CONCLUSION: Clinical, histological, therapeutic and evolutive aspects of this uncommon entity will be reviewed.


Assuntos
Hematopoese , Hidroxiureia/uso terapêutico , Derrame Pleural/tratamento farmacológico , Feminino , Hematopoese/efeitos dos fármacos , Humanos , Pessoa de Meia-Idade , Derrame Pleural/etiologia
4.
Bull Cancer ; 87(7-8): 600-3, 2000 Jul.
Artigo em Francês | MEDLINE | ID: mdl-10969216

RESUMO

Most teams working on sentinel node biopsy in the treatment of breast cancer inject either radioactive colloid or vital blue dye around the primary tumour. Many anatomical studies and lymphoscintigraphical studies, some very old, have shown that the lymphatic drainage of the breast is collected first in the periareolar plexus of Sappey, then routed to the axilla in 95% of cases, via one or two primary collectors. In a series of 94 breast cancers measuring less than 3 cm, with any palpable axillary lymph node, 2 ml of patent blue was injected intradermally around the areola, at the two meridians around the tumor. The sentinel node was identified in 89 cases (94,7%), regardless of the location of the primary tumor. All the sentinel nodes were located in the lower axilla. An average of 1.6 nodes were found per patient. In 41 cases, axillary lymph node dissection was performed either immediately (5 technical failures, 9 positive frozen section) or delayed only if the sentinel node was positive, either on standard H&E staining or on immunohistochemistry (27 cases). Thus, axillary lymph node dissection was not performed in 48 patients (55%). In positive node patient, the sentinel node was the only positive lymph node in 20 patients (55%). For 5 positive node patients, axillary lymph node dissection was not performed: poor vital status (2 micro-metastatic nodes) or by decision of patient (3 IHC positive nodes). With this periareolar injection procedure, the rate of detection is highly satisfactory and is comparable to that usually published with peritumoral injection. This procedure seems appropriate in all cases, regardless of the topography, the size or the multifocality of breast cancer.


Assuntos
Neoplasias da Mama/patologia , Corantes/administração & dosagem , Linfonodos/patologia , Mamilos , Corantes de Rosanilina/administração & dosagem , Axila , Feminino , Humanos , Injeções/métodos , Excisão de Linfonodo , Metástase Linfática , Estadiamento de Neoplasias/métodos , Sensibilidade e Especificidade
5.
Bull Cancer ; 86(6): 529-36, 1999 Jun.
Artigo em Francês | MEDLINE | ID: mdl-10417426

RESUMO

Non-Hodgkin's lymphoma consists of a group of disorders which is increasing for the last decades. In the USA, since the early 1970s, the incidence rate has increased by almost 60% and ranges from 3 to 4% per year, which is faster than for the majority of cancers. Important advances in our knowledge of histopathology together with new diagnostic tools, as well as the improvement of the registered data and ageing of the population, only partially explain this increase. Two viruses have been identified as possible etiologic agents for non-Hodgkin's lymphoma: the Epstein-Barr virus and HTLV-I. More recently, HHV8 and the hepatitis C virus have been incriminated in the occurrence of non-Hodgkin's lymphomas. Congenital and acquired immunodeficiencies (due to immunosuppressive therapy and viral disease such as Aids) might also represent predisposing factors. However, the epidemic HIV infection is the most strongly correlated with the increasing incidence of non-Hodgkin's lymphoma in the United States. Finally, epidemiologic studies indicate that environmental factors may play an important role in the etiology of non-Hodgkin's lymphoma, specially toxic chemicals used in farming.


Assuntos
Linfoma não Hodgkin/epidemiologia , Adulto , Criança , Exposição Ambiental/efeitos adversos , Saúde Global , Humanos , Incidência , Linfoma não Hodgkin/etiologia , Linfoma não Hodgkin/patologia , Viroses/complicações
6.
J Clin Endocrinol Metab ; 98(1): 1-6, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23162095

RESUMO

CONTEXT: Bone giant cell tumors (GCTs) are among the most common benign bone tumors and affect mostly young patients. They represent a rare etiology of head and neck cancer. OBJECTIVE: We report the case of a 38-yr-old male with a GCT of the thyroid cartilage, initially treated as a thyroid cancer. CASE ILLUSTRATION: The patient had incomplete initial surgery, and a substantial tumor residue was observed at postoperative morphological evaluation. Given the potential risks associated with complete definitive surgery and recent data supporting the use of the receptor activator of nuclear factor κB ligand inhibitor, we proposed treatment with denosumab. Three months after initiating denosumab, computed tomography scan imaging showed a significant modification of the lesion with several calcifications. The patient underwent partial laryngectomy, and examination of the surgical specimen revealed a complete histological response. RESULTS: A review of the literature was conducted to identify previous studies pertaining to GCTs, focusing on reports related to their management. CONCLUSION: Denosumab emerges as a new treatment for patients with GCTs. Additional clinical trial data are needed to establish the real efficacy and long-term safety of this treatment for the management of GCT.


Assuntos
Tumores de Células Gigantes/diagnóstico , Neoplasias da Glândula Tireoide/diagnóstico , Adulto , Anticorpos Monoclonais Humanizados/uso terapêutico , Antineoplásicos/uso terapêutico , Terapia Combinada , Denosumab , Tumores de Células Gigantes/tratamento farmacológico , Tumores de Células Gigantes/patologia , Tumores de Células Gigantes/cirurgia , Humanos , Masculino , Neoplasia Residual , Neoplasias da Glândula Tireoide/tratamento farmacológico , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/cirurgia
9.
Br J Haematol ; 138(3): 316-23, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17555470

RESUMO

Well-established histopathological prognostic factors are lacking in primary central nervous system (CNS) lymphomas (PCNSL). The present study investigated the presence and prognostic role of tumour necrosis (TN) and reactive perivascular T-cell infiltrate (RPVI), defined as a rim of small reactive T-lymphocytes occurring alone or located between the vascular wall and large neoplastic cells, in tumour samples from 100 immunocompetent patients with PCNSL. World Health Organization histotypes of the patients were: 96 diffuse large B-cell lymphomas, two Burkitt-like lymphomas, one anaplastic large T-cell lymphoma and one unclassified B-cell lymphoma. TN was observed in 24 (24%) cases and RPVI in 26 (36%) of 73 assessable cases. Patients with RPVI-positive lesions exhibited a significantly better overall survival (OS) than patients with RPVI-negative lymphoma, particularly among patients treated with high-dose methotrexate-based chemotherapy (3-year OS: 59 +/- 14% vs. 42 +/- 9%, P = 0.02). By contrast, the presence of TN did not demonstrate prognostic significance. Multivariate analysis confirmed an independent association between RPVI and survival. In conclusion, the presence of RPVI is independently associated with survival in PCNSL. This parameter can be easily and routinely assessed at diagnosis on histopathological specimens.


Assuntos
Neoplasias do Sistema Nervoso Central/imunologia , Linfoma de Células B/imunologia , Linfócitos T/patologia , Adulto , Idoso , Linfócitos B/patologia , Vasos Sanguíneos , Neoplasias do Sistema Nervoso Central/mortalidade , Feminino , Humanos , Ativação Linfocitária , Linfoma de Células B/mortalidade , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Pericitos/patologia , Prognóstico , Taxa de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA